THE TRIAL

The One That Was Always Going to Be Harder Than It Looked

Every year at the European Association for the Study of Diabetes, the pharmaceutical industry shows up with numbers, and most of the numbers blend into each other by Thursday afternoon. The ones from this October were different. On October 1, Boehringer Ingelheim and Zealand Pharma published the results of SYNCHRONIZE-2 in the New England Journal of Medicine — the first Phase 3 trial to test survodutide specifically in people with both obesity and type 2 diabetes. The [SYNCHRONIZE-2 results](https://www.boehringer-ingelheim.com/human-health/crm-health/metabolic-health/survodutide-synchronize-2-phase-3-obesity-type-2-diabetes-results) covered 48 weeks of treatment, enrolled more than 600 patients, and tested a drug that works differently from every approved medication on the market. Survodutide is a dual agonist — it activates both the GLP-1 receptor and the glucagon receptor simultaneously. GLP-1 alone suppresses appetite and slows gastric emptying; glucagon activation, counterintuitively, increases energy expenditure. The hypothesis is that hitting both receptors produces better metabolic outcomes than either alone, and the [Zealand Pharma announcement](https://www.globenewswire.com/news-release/2026/10/01/3372565/0/en/zealand-pharma-announces-boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-.html) called the results a significant step forward. The published data suggests that framing is, for once, not entirely marketing.

THE NUMBERS

13.1 Percent. And the Other Number.

The headline from SYNCHRONIZE-2 is a 13.1% reduction in body weight, compared to 3.1% for placebo, measured at 48 weeks using the efficacy estimand — the analysis accounts for weight participants would have lost had they stayed on the drug rather than discontinuing — and against a type 2 diabetes population, where GLP-1s typically underperform their obesity-only numbers, that figure is notable. For context, semaglutide at the Ozempic dose approved for diabetes produces roughly 6 to 8% weight loss in the SUSTAIN trial data. But the number that has drawn more attention from metabolic researchers than from the morning headlines is the HbA1c change: survodutide reduced glycated hemoglobin by 1.21 percentage points versus 0.03 for placebo — meaningful glycemic control in a population that already has impaired glucose regulation. The combination of meaningful weight loss and meaningful glycemic control in a single agent is exactly what dual agonism has been promising for years, and the [trial registration at ClinicalTrials.gov](https://clinicaltrials.gov/search?term=survodutide%20BI%20456906) shows SYNCHRONIZE-2 was precisely designed to demonstrate both. Whether those two numbers are good enough to earn FDA approval is a separate — and considerably more complicated — question.

THE COMPETITION

Ahead of Ozempic. Behind Zepbound. And Still Missing the Cardiovascular Story.

Survodutide is entering a market that already has two drugs that work very well. Semaglutide produced 14.9% weight loss in its STEP-1 obesity trial; in the type 2 diabetes population, that number falls to roughly 6 to 8%. Tirzepatide posted 20.9% weight loss in SURMOUNT-1 and roughly 15% in T2D patients in SURPASS-2. Survodutide's 13.1% in T2D sits between those data points — it beats semaglutide's metabolic performance in diabetes and trails tirzepatide's, which is a positioning problem worth naming clearly for a drug that is not yet approved. The more consequential gap in the SYNCHRONIZE-2 dataset is the one that does not appear in it at all: cardiovascular outcomes. SYNCHRONIZE-CVOT, the dedicated cardiovascular outcomes trial for survodutide, is still ongoing, and for an obesity and diabetes drug to reach broad clinical adoption, regulators and payers want to see that it reduces the risk of heart attack, stroke, or cardiovascular death — not just that it moves the scale. Semaglutide and tirzepatide have that data. Survodutide does not yet, and [the FDA has made its position on unapproved GLP-1 class drugs explicit](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss).

WHAT IT MEANS

A Trial Isn't a Drug. A Drug Isn't a Prescription.

Here is where most coverage of SYNCHRONIZE-2 has gotten something quietly wrong: a Phase 3 publication in the New England Journal of Medicine is not the same thing as a drug approval, a drug approval is not the same thing as broad access, and broad access is not the same thing as a prescription in front of you. For a drug at survodutide's current stage, the distance between trial results published in October and a drug available at a pharmacy near you is measured in years — regulatory submission, agency review, labeling negotiations, pricing decisions, payer formulary placement, and physician adoption lag all stand between SYNCHRONIZE-2 and any individual patient's clinic visit. What the data from this trial actually does is change the scientific question. The question about survodutide was previously whether the glucagon component would compromise tolerability — the heart rate elevation seen in early trials, roughly 3.4 beats per minute above placebo, was a signal researchers watched closely — or whether the dual mechanism would produce cardiovascular risk above what the GLP-1 component alone would generate. SYNCHRONIZE-2's efficacy data is stronger than some analysts predicted, and the unknowns remain real: the CVOT result, the long-term weight maintenance trajectory, and the clinical positioning against two drugs that already own the market conversation. Based on [the peer-reviewed literature available through PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=survodutide%20BI%20456906), survodutide has genuine Phase 3 data, is still in the middle of its regulatory journey, and is not at the end of it. Interesting enough to watch. Too early for certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.